DRUGS manufacturer SCM Pharma is investing £500,000 in its Northumberland plant as it increases capacity to meet growing demand from US customers.
The Prudhoe pharmaceutical company is also gearing up to use the Interphex Exhibition in New York next month as the platform to showcase its capability to the US. The event is one of the world’s largest meeting places for those involved in drug manufacturing.
SCM has previously focused on winning business in the UK and the Continent but has growing hopes for the US and Far East to boost revenues.
The business, which has more than 50 staff, is investing in new facilities to make high-potency drugs to meet growing demand for these specialist products and is now one of few firms in the world capable of making them.
Managing director Dianne Sharpe said: “As the business has developed and grown over the past few years, we have always tried to adapt to our clients’ changing and increasing product-manufacturing requirements.
“We have, therefore, invested heavily into modifying the facility to ensure we can efficiently deal with a range of different potent projects including small pilot scale, clinical trial progression and the commercial supply of licensed medicines.
“It’s a very exciting time for the business as we now have more flexibility and superior capability to handle multiple productions at any one time. “